Posted on 26/04/2011 in Pharmaceutical Company Product News
Merck Sharpe and Dohme and its partner Sanofi Pasteur have commenced a clinical study of a new vaccine designed to treat a range of diseases among children.
The companies have begun a phase III study of the hexavalent combination vaccine that will test the safety and immunogenicity of the drug when administered concomitantly with Prevnar 13 and Rotateq.
Leave a Reply